Checkpoint Signaling, Base Excision Repair, and PARP Promote Survival of Colon Cancer Cells Treated with 5-Fluorodeoxyuridine but Not 5-Fluorouracil

Molecular Genetics of Colorectal Cancer

(2011) Eric R. Fearon   Annual Review of Pathology-Mechanisms of Disease

Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells

(2011) A. M. Huehls et al.   CANCER RESEARCH

The Incorporation of 5-Fluorouracil into RNA Affects the Ribonucleolytic Activity of the Exosome Subunit Rrp6

(2011) R. A. Silverstein et al.   MOLECULAR CANCER RESEARCH

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation

(2011) Henrik Sahlin Pettersen et al.   NUCLEIC ACIDS RESEARCH

Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?

(2010) Raafat A. El-Awady et al.   ANTI-CANCER DRUGS

Effect of the Thymidylate Synthase Inhibitors on dUTP and TTP Pool Levels and the Activities of DNA Repair Glycosylases on Uracil and 5-Fluorouracil in DNA

(2010) Breeana C. Grogan et al.   BIOCHEMISTRY

5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency

(2010) K Bracht et al.   BRITISH JOURNAL OF CANCER

Heat Shock Protein 90 Inhibition Depletes LATS1 and LATS2, Two Regulators of the Mammalian Hippo Tumor Suppressor Pathway

(2010) C. J. Huntoon et al.   CANCER RESEARCH

Microsatellite Instability in Colorectal Cancer

(2010) C. Richard Boland et al.   GASTROENTEROLOGY

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalizing Therapy for Ovarian Cancer:BRCAness and Beyond

(2010) Robert C. Bast et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Genome-Wide mRNA and microRNA Profiling of the NCI 60 Cell-Line Screen and Comparison of FdUMP[10] with Fluorouracil, Floxuridine, and Topoisomerase 1 Poisons

(2010) W. H. Gmeiner et al.   MOLECULAR CANCER THERAPEUTICS

ATR: a master conductor of cellular responses to DNA replication stress

(2010) Rachel Litman Flynn et al.   TRENDS IN BIOCHEMICAL SCIENCES

Limits to Thymidylate Synthase and TP53 Genes as Predictive Determinants for Fluoropyrimidine Sensitivity and Further Evidence for RNA-Based Toxicity as a Major Influence

(2009) J. R. Brody et al.   CANCER RESEARCH

Clinical implications of microsatellite instability in sporadic colon cancers

(2009) Frank A Sinicrope et al.   CURRENT OPINION IN ONCOLOGY

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line

(2009) Renata Matuo et al.   JOURNAL OF APPLIED TOXICOLOGY

Reduced ATR or Chk1 Expression Leads to Chromosome Instability and Chemosensitization of Mismatch Repair–deficient Colorectal Cancer Cells

(2009) Melanie J. Jardim et al.   MOLECULAR BIOLOGY OF THE CELL

Impairment of APE1 Function Enhances Cellular Sensitivity to Clinically Relevant Alkylators and Antimetabolites

(2009) D. R. McNeill et al.   MOLECULAR CANCER RESEARCH

The role of floxuridine in metastatic liver disease

(2009) D. G. Power et al.   MOLECULAR CANCER THERAPEUTICS

Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance

(2009) R. Humeniuk et al.   MOLECULAR CANCER THERAPEUTICS

Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival

(2009) J. M. Wagner et al.   MOLECULAR PHARMACOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Base Excision by Thymine DNA Glycosylase Mediates DNA-Directed Cytotoxicity of 5-Fluorouracil

(2009) Christophe Kunz et al.   PLOS BIOLOGY

Uracil in DNA: Consequences for carcinogenesis and chemotherapy

(2008) Sondra H. Berger et al.   BIOCHEMICAL PHARMACOLOGY

Participation of DNA repair in the response to 5-fluorouracil

(2008) M. D. Wyatt et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

DNA repair deficiency as a therapeutic target in cancer

(2008) Sarah A Martin et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine

(2008) Angen Liu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

The RNA Exosome Component hRrp6 Is a Target for 5-Fluorouracil in Human Cells

(2008) S. Kammler et al.   MOLECULAR CANCER RESEARCH

Evidence that tRNA modifying enzymes are important in vivo targets for 5-fluorouracil in yeast

(2008) M. Gustavsson et al.   RNA

Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase

(2007) Yuhong Luo et al.   DNA REPAIR